- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01739556
On-treatment PLAtelet Reactivity-guided Therapy Modification FOR ST-segment Elevation Myocardial Infarction (PLATFORM)
On-treatment PLAtelet Reactivity-guided Therapy Modification FOR ST-segment Elevation Myocardial Infarction (PLATFORM)
Adequate platelet inhibition with dual antiplatelet therapy is a key therapeutic goal after primary percutaneous coronary intervention (PPCI), aimed at protecting against stent thrombosis and increased mortality. Recent aggregometric assays have shown that up to one third of acute coronary syndrome patients treated with clopidogrel have incomplete inhibition of adenosine diphosphate(ADP)-induced platelet aggregation while the number of patients treated with aspirin who have incomplete inhibition of thromboxane A2-induced platelet aggregation (ASPI)is much lower. High on-treatment platelet reactivity (HTPR) has been associated with an increased rate of ischemic events after PCI. However, recent large trials did not show a clinical benefit of TPR-guided therapy modification in acute coronary syndrome patients treated by PCI.
On-treatment PLAtelet reactivity-guided Therapy modification FOR ST-segment elevation Myocardial infarction (PLATFORM) is an investigator-initiated, prospective, randomized, parallel-group, controlled clinical trial designed to test the hypothesis that antiplatelet therapy modification is superior to standard antiplatelet regimen among intermediate to high-risk STEMI patients undergoing PPCI. The safety hypothesis is that compared with control arm, interventional study arm will have similar rates of non-coronary artery bypass graft surgery-related bleeding. Approximately 632 ST-elevation myocardial infarction (STEMI) patients with intermediate to high-risk (RISK-PCI score >3) clinical features undergoing PPCI will be randomly allocated to treatment modification or standard treatment. Low responders to aspirin will receive 200 mg aspirin for 30 days. Low responders to clopidogrel will receive 180 mg ticagrelor for 1 year. Patients will be followed up to 1 year after PPCI.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
On-treatment PLAtelet reactivity-guided Therapy modification FOR ST-segment elevation Myocardial infarction (PLATFORM) is an investigator-initiated, prospective, open-label, randomized, parallel-group, actively controlled single-centre clinical trial. The research protocol has been approved by the Ethics Committee of the Clinical Centre of Serbia. All participants will have to provide their informed consent in writing. The trial design will ensure that all participants abide by good clinical practice and the ethical principles of the Declaration of Helsinki II. Patients will be randomly allocated to antiplatelet regimen modification (ARM, interventional arm) or standard treatment (control arm) using a computer-generated 1:1 simple randomization scheme. TPR will be assessed in patients enrolled in the intervention arm of the trial. Low responders to aspirin will receive 200 mg aspirin for 30 days. Low responders to clopidogrel will receive 180 mg ticagrelor for 1 year. Patients enrolled in the control arm will receive standard antiplatelet regimen including 100 mg aspirin and 75 mg clopidogrel without assessment of TPR. The treating physicians will not be blinded to the intervention since an open design will make it possible for investigators to perform necessary adjustments of the antiplatelet regimen in accordance with TPR status. To minimize any possible bias inherent in the open design, endpoints will be evaluated by a blinded endpoint committee. Enrollment will start in June 2013. Recruitment will continue until 632 patients have been randomized. The end of the recruitment period is planned for June 2015. The trial will continue until all available survivors have been followed for at least 1 year.
Aspirin 300 mg and clopidogrel 600 mg loading doses will be administered as early as possible before PPCI. Primary PCI will be performed via femoral or radial approach, using standard 6 French-7 French guiding catheters. The Thrombolysis in Myocardial Infarction (TIMI) blood flow will be measured by two experienced observers blinded to identity and the order of angiograms. Any disagreement will be resolved by a third observer. Unfractionated heparin will be started as 100 IU/kg bolus (60 IU/kg if glycoprotein (GP)IIb/IIIa receptor inhibitor was used); the 12 IU/kg/h infusion will follow if clinically indicated. Proton-pump inhibitor pantoprazole or H2-blocker ranitidine will be given to selected patients at risk for gastrointestinal hemorrhage. GP IIb/IIIa receptor inhibitor tirofiban will be administered during the procedure in patients with evidence of high intracoronary thrombus burden according to the European Society of Cardiology guidelines.
Multiple electrode aggregometry will be performed using the impedance aggregometer and under the monitoring of an official representative of the manufacturer (Multiplate analyzer, Verum-Diagnostics, Munich, Germany). TPR results will be evaluated by 2 investigators who will be blinded to patient's identity and treatment. Whole blood will be sampled 24 hours after the loading dose. In patients who received IIb/IIIa inhibitor tirofiban blood samples will be obtained at least 24 hours after the completion of tirofiban infusion. On-treatment platelet reactivity (TPA) above 50%, compared to the basal value estimated by TRAP test, will be linked with low responsiveness.
Patients will be followed-up after discharge from hospital for net adverse events up to 1 year after enrolment by scheduled telephone interviews and outpatient visits. Interviewers will be blinded to the randomization scheme and to the results of platelet aggregation. An independent Clinical Event Committee, composed of 3 cardiologists and 1 neurologist and blinded with respect to randomization allocation will review and adjudicate the occurrence of each suspected clinical end point. Interim analyses of efficacy and futility, using O'Brian-Fleming guidelines for group sequential design, are planned when one fourth, one half and three fourths of the maximum number of the 632 patients had been followed-up for 30 days. Interim analyses and all safety data will be reviewed by an independent Data Safety and Monitoring Committee, composed of a chairman, a statistician, and 2 physician members.
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Belgrade, Serbia, 11000
- Clinical Centre of Serbia, Emergency Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- 18 years and older, willing consent, undergoing primary PCI for STEMI, within 12 hours of the onset of symptoms, stent implanted successfully, RISK-PCI score for 30-day MACE >3, alive 24 hours after loading doses, ability to comply with study protocol, negative pregnancy test for women of childbearing potential before enrollment, agree to use a reliable method of birth control during the study
Exclusion Criteria:
- Pre-procedural
- history of hemorrhagic stroke
- ischemic stroke within 30 days of randomization
- evidence of active abnormal bleeding within 3 months of randomization
- high risk for bleeding on long-term antiplatelet therapy
- current therapy with coumadin anticoagulant
- Pregnancy or nursing
- current enrollment in another investigational study Procedural
- balloon angioplasty without stent placement
- unsuccessful PPCI (post-procedural TIMI flow 0) Post-procedural
- active bleeding
- hemoglobin <10 g/dL or drop in hemoglobin by ≥3 g/dL
- platelet count <100 000 x 10-9/L.
- TRAP value <500 aggregation units
- indication for permanent anticoagulant therapy
- need for urgent surgical revascularization
- vascular pseudoaneurysm
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Intervention Arm
Antiplatelet regimen modification will be guided by assessment of the on-treatment platelet reactivity.
Low responders to aspirin will receive 200 mg aspirin for 30 days.
Low responders to clopidogrel will receive 180 mg ticagrelor for 1 year.
|
|
No Intervention: Standard Treatment
Patients enrolled in the Standard Treatment arm will receive standard antiplatelet regimen including 100 mg aspirin and 75 mg clopidogrel without assessment of on-treatment platelet reactivity.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
MACE
Time Frame: up to 1 year
|
The PLATFORM specified primary efficacy end point is the time to first occurrence of any component of the composite MACE (comprising total death, nonfatal infarction, nonfatal stroke and immediate target vessel revascularization).
|
up to 1 year
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Total death
Time Frame: up to 1 year
|
total mortality rate
|
up to 1 year
|
Major bleeding
Time Frame: up to 1 year
|
TIMI major bleeding unrelated to coronary artery bypass graft surgery
|
up to 1 year
|
Total bleeding
Time Frame: up to 1 year
|
all bleeding events
|
up to 1 year
|
Reinfarction
Time Frame: up to 1 year
|
nonfatal myocardial infarction
|
up to 1 year
|
Stroke
Time Frame: up to 1 year
|
nonfatal cerebrovascular insult
|
up to 1 year
|
Revascularisation
Time Frame: up to 1 year
|
ischemia-driven target vessel revascularization
|
up to 1 year
|
Transfusion
Time Frame: up to 1 year
|
need for bood transfusion
|
up to 1 year
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Stent thrombosis
Time Frame: up to 1 year
|
definite stent thrombosis
|
up to 1 year
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Igor Mrdovic, Ph.D, Clinical Centre of Sebria
- Study Director: Jovan Perunicic, Ph.D, Clinical Centre of Serbia
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Ischemia
- Pathologic Processes
- Necrosis
- Myocardial Ischemia
- Heart Diseases
- Cardiovascular Diseases
- Vascular Diseases
- Myocardial Infarction
- Infarction
- ST Elevation Myocardial Infarction
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Peripheral Nervous System Agents
- Enzyme Inhibitors
- Analgesics
- Sensory System Agents
- Anti-Inflammatory Agents, Non-Steroidal
- Analgesics, Non-Narcotic
- Anti-Inflammatory Agents
- Antirheumatic Agents
- Fibrinolytic Agents
- Fibrin Modulating Agents
- Platelet Aggregation Inhibitors
- Cyclooxygenase Inhibitors
- Antipyretics
- Purinergic P2Y Receptor Antagonists
- Purinergic P2 Receptor Antagonists
- Purinergic Antagonists
- Purinergic Agents
- Aspirin
- Ticagrelor
Other Study ID Numbers
- CCS-553-12
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Acute ST-elevation Myocardial Infarction
-
Azienda ULSS 5 PolesanaUniversity of PadovaUnknownMyocardial Infarction, Acute | ST Segment Elevation Myocardial Infarction | Non-ST Elevation Myocardial Infarction (nSTEMI)Italy
-
Stony Brook UniversityHennepin County Medical Center, MinneapolisUnknownAcute Coronary Syndrome | STEMI | NSTEMI - Non-ST Segment Elevation MI | Non ST Segment Elevation Myocardial Infarction | Non-ST Elevation Myocardial Infarction | STEMI - ST Elevation Myocardial Infarction | Acute Coronary Artery Thrombosis (Diagnosis) | Non ST Segment Elevation Acute Coronary Syndrome and other conditionsUnited States
-
Henry Ford Health SystemAbiomed Inc.Enrolling by invitationAcute Myocardial Infarction | Cardiogenic Shock | STEMI | NSTEMI - Non-ST Segment Elevation MI | STEMI - ST Elevation Myocardial Infarction | NSTEMI | Acute Myocardial Infarction With ST Elevation | Acute Myocardial Infarction of Right Ventricle (Disorder) | Acute Myocardial Infarction of Left VentricleUnited States
-
Medical Center of South ArkansasWithdrawnAcute Coronary Syndrome | Acute ST Segment Elevation Myocardial InfarctionUnited States
-
Karolinska InstitutetThe Swedish Research Council; Swedish Heart Lung Foundation; Swedish Foundation...CompletedAcute Coronary Syndrome | Angina, Unstable | Acute ST Segment Elevation Myocardial Infarction | Non-ST Elevation (NSTEMI) Myocardial InfarctionSweden
-
Second Affiliated Hospital, School of Medicine,...Not yet recruitingAcute Anterior ST Segment Elevation Myocardial Infarction
-
Henan Institute of Cardiovascular EpidemiologyRecruiting
-
Terumo Europe N.V.CompletedAcute ST Segment Elevation Myocardial InfarctionBrazil, Serbia, Italy, Spain, Macedonia, The Former Yugoslav Republic of
-
RenJi HospitalCompletedAcute ST-segment Elevation Myocardial InfarctionChina
-
Second Hospital of Jilin UniversityUnknownAcute ST Segment Elevation Myocardial InfarctionChina
Clinical Trials on Antiplatelet Regimen Modification (aspirin or ticagrelor)
-
The Third Xiangya Hospital of Central South UniversityCompletedCoronary Heart DiseaseChina
-
Ottawa Heart Institute Research CorporationSuspendedMyocardial Infarction | Coronary Artery DiseaseCanada
-
Harbin Medical UniversityLanZhou University; Hebei General Hospital; The First Hospital of Jilin University and other collaboratorsActive, not recruiting
-
Xuanwu Hospital, BeijingRecruitingIschemic Stroke | Vertebral Artery StenosisChina
-
Beijing Tiantan HospitalNot yet recruiting
-
Hospital Israelita Albert EinsteinRecruiting
-
Second Affiliated Hospital, School of Medicine,...CompletedCoronary Heart DiseaseChina
-
Nanjing First Hospital, Nanjing Medical UniversityActive, not recruitingCoronary Artery DiseaseChina
-
Yonsei UniversityRecruitingAcute Coronary SyndromeKorea, Republic of
-
Jiangsu HengRui Medicine Co., Ltd.Completed